PDF(Pubmed)
Abstract：
UNASSIGNED: This meta-analysis aimed to assess the effectiveness and safety of novel antiepileptic drugs (AEDs) in treating epilepsy in patients with brain tumors (BTRE).
UNASSIGNED: A search was conducted on PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to February 2023, with English language restriction.
UNASSIGNED: In this meta-analysis, 18 clinical trials involving 755 BTRE patients were included to assess the efficacy and safety of novel AEDs in BTRE treatment. At the last follow-up, a ≥50% reduction in seizure frequency was experienced by 72% of patients (random-effects model, 95% CI = 0.64-0.78) using novel AEDs. At the last follow-up, seizure freedom was experienced by 34% of patients (random-effects model, 95% CI = 0.28-0.41) using novel AEDs. The pooled incidence of AEs was found to be 19% (95% CI: 13%-26%), with a withdrawal rate due to adverse effects of only 3%. Comparable efficacy and incidence of adverse effects were observed between lacosamide and perampanel.
UNASSIGNED: This meta-analysis suggests that novel antiepileptic drugs are deemed effective for seizure control in brain tumor patients, particularly when used as adjunctive therapy. Although lacosamide and perampanel received more focus in studies, no significant difference was observed in the efficacy and adverse reactions of these two drugs in seizure control. Further randomized controlled trials are deemed necessary to validate our findings.
UNASSIGNED: A search was conducted on PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to February 2023, with English language restriction.
UNASSIGNED: In this meta-analysis, 18 clinical trials involving 755 BTRE patients were included to assess the efficacy and safety of novel AEDs in BTRE treatment. At the last follow-up, a ≥50% reduction in seizure frequency was experienced by 72% of patients (random-effects model, 95% CI = 0.64-0.78) using novel AEDs. At the last follow-up, seizure freedom was experienced by 34% of patients (random-effects model, 95% CI = 0.28-0.41) using novel AEDs. The pooled incidence of AEs was found to be 19% (95% CI: 13%-26%), with a withdrawal rate due to adverse effects of only 3%. Comparable efficacy and incidence of adverse effects were observed between lacosamide and perampanel.
UNASSIGNED: This meta-analysis suggests that novel antiepileptic drugs are deemed effective for seizure control in brain tumor patients, particularly when used as adjunctive therapy. Although lacosamide and perampanel received more focus in studies, no significant difference was observed in the efficacy and adverse reactions of these two drugs in seizure control. Further randomized controlled trials are deemed necessary to validate our findings.
摘要：
■这项荟萃分析旨在评估新型抗癫痫药物（AEDs）治疗脑肿瘤（BTRE）患者癫痫的有效性和安全性。
■在PubMed上进行了搜索，EMBASE,WebofScience,和Cochrane图书馆从成立到2023年2月，英语限制。
■在此荟萃分析中，纳入了18项涉及755名BTRE患者的临床试验，以评估新型AEDs在BTRE治疗中的疗效和安全性。在最后一次随访中，72%的患者癫痫发作频率降低≥50%(随机效应模型，95%CI=0.64-0.78)使用新型AED。在最后一次随访中，34%的患者经历了癫痫发作自由(随机效应模型，95%CI=0.28-0.41)使用新型AED。合并的不良事件发生率为19%（95%CI：13%-26%），由于不利影响，退出率仅为3%。在拉科沙胺和perampanel之间观察到相当的疗效和不良反应发生率。
■这项荟萃分析表明，新型抗癫痫药物被认为对脑肿瘤患者的癫痫发作控制有效，特别是当用作辅助治疗时。尽管拉科沙胺和帕潘妮在研究中得到了更多的关注，这两种药物在癫痫发作控制中的疗效和不良反应没有显着差异。进一步的随机对照试验被认为有必要验证我们的发现。
■在PubMed上进行了搜索，EMBASE,WebofScience,和Cochrane图书馆从成立到2023年2月，英语限制。
■在此荟萃分析中，纳入了18项涉及755名BTRE患者的临床试验，以评估新型AEDs在BTRE治疗中的疗效和安全性。在最后一次随访中，72%的患者癫痫发作频率降低≥50%(随机效应模型，95%CI=0.64-0.78)使用新型AED。在最后一次随访中，34%的患者经历了癫痫发作自由(随机效应模型，95%CI=0.28-0.41)使用新型AED。合并的不良事件发生率为19%（95%CI：13%-26%），由于不利影响，退出率仅为3%。在拉科沙胺和perampanel之间观察到相当的疗效和不良反应发生率。
■这项荟萃分析表明，新型抗癫痫药物被认为对脑肿瘤患者的癫痫发作控制有效，特别是当用作辅助治疗时。尽管拉科沙胺和帕潘妮在研究中得到了更多的关注，这两种药物在癫痫发作控制中的疗效和不良反应没有显着差异。进一步的随机对照试验被认为有必要验证我们的发现。
